[go: up one dir, main page]

TN2010000210A1 - Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same - Google Patents

Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same

Info

Publication number
TN2010000210A1
TN2010000210A1 TN2010000210A TN2010000210A TN2010000210A1 TN 2010000210 A1 TN2010000210 A1 TN 2010000210A1 TN 2010000210 A TN2010000210 A TN 2010000210A TN 2010000210 A TN2010000210 A TN 2010000210A TN 2010000210 A1 TN2010000210 A1 TN 2010000210A1
Authority
TN
Tunisia
Prior art keywords
hgm
csf
monoclonal antibodies
bind
same
Prior art date
Application number
TN2010000210A
Other languages
English (en)
Inventor
Kenzo Takada
Kantou Nakajima
Barbara Kistler
John Park
Original Assignee
Evec Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evec Inc, Boehringer Ingelheim Int filed Critical Evec Inc
Publication of TN2010000210A1 publication Critical patent/TN2010000210A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TN2010000210A 2007-11-13 2010-05-12 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same TN2010000210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294945 2007-11-13
JP2008052471 2008-02-14
PCT/US2008/012680 WO2009064399A1 (fr) 2007-11-13 2008-11-12 Anticorps monoclonaux qui se lient au hgm-csf et compositions médicales les comprenant

Publications (1)

Publication Number Publication Date
TN2010000210A1 true TN2010000210A1 (en) 2011-11-11

Family

ID=40329216

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2010000210A TN2010000210A1 (en) 2007-11-13 2010-05-12 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same

Country Status (31)

Country Link
US (2) US8679502B2 (fr)
EP (3) EP2215119B1 (fr)
KR (1) KR20100102108A (fr)
CN (2) CN104072613A (fr)
AR (1) AR069290A1 (fr)
AU (1) AU2008321429A1 (fr)
BR (1) BRPI0820530A2 (fr)
CA (1) CA2705539A1 (fr)
CL (1) CL2008003361A1 (fr)
CO (1) CO6382188A2 (fr)
DK (1) DK2215119T3 (fr)
EC (1) ECSP10010251A (fr)
ES (1) ES2401536T3 (fr)
HR (1) HRP20130204T1 (fr)
IL (1) IL205576A0 (fr)
MA (1) MA31899B1 (fr)
ME (1) ME01005B (fr)
MX (1) MX2010005291A (fr)
NZ (2) NZ586027A (fr)
PE (1) PE20091420A1 (fr)
PL (1) PL2215119T3 (fr)
PT (1) PT2215119E (fr)
RS (1) RS52713B (fr)
RU (2) RU2517596C2 (fr)
SG (1) SG176499A1 (fr)
SI (1) SI2215119T1 (fr)
TN (1) TN2010000210A1 (fr)
TW (2) TW201206955A (fr)
UY (1) UY31466A1 (fr)
WO (1) WO2009064399A1 (fr)
ZA (1) ZA201003467B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20110044996A1 (en) * 2007-05-23 2011-02-24 Charles Mackay Neutralizing antibodies
EP2217626A4 (fr) * 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd Epitope pour la neutralisation d'anticorps
PL2215119T3 (pl) 2007-11-13 2013-06-28 Evec Inc Przeciwciała monoklonalne, które wiążą się z hGM-CSF i kompozycje lecznicze je zawierające
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
JP5727379B2 (ja) 2008-12-22 2015-06-03 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 変形性関節症の治療
US8475796B2 (en) 2008-12-22 2013-07-02 University Of Melbourne Method of treating pain using an antagonist of GM-CSF
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
RU2013156435A (ru) 2011-07-06 2015-08-20 МорфоСис АГ Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения
WO2014044768A1 (fr) * 2012-09-20 2014-03-27 Morphosys Ag Traitement de la polyarthrite rhumatoïde
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
MX385854B (es) 2013-08-30 2025-03-18 Takeda Pharmaceuticals Co Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
EP3368561B1 (fr) * 2015-10-30 2025-09-17 Medimmune Limited Prévention de troncature n-terminale dans les chaînes légères des igg
IL265331B2 (en) * 2016-09-19 2024-01-01 I Mab Anti-GM-CSF antibodies and uses thereof
CN116199785A (zh) * 2017-06-25 2023-06-02 西雅图免疫公司 多特异性抗体及其制备和使用方法
AU2018396964C1 (en) 2017-12-28 2024-10-03 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
EP3623382A1 (fr) * 2018-09-14 2020-03-18 Universität Zürich Ligands vers gm-csf ou un récepteur gm-csf destinés à être utilisés dans une leucémie chez un patient ayant subi une allo-hct
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US12419824B2 (en) 2019-02-08 2025-09-23 Lubrizol Advanced Materials, Inc. Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
WO2025221669A1 (fr) * 2024-04-18 2025-10-23 Promab Biotechnologies, Inc. Protéine de fusion comprenant il-12 et gm-csf
CN120399067B (zh) * 2025-07-02 2025-09-30 武汉伊莱瑞特生物科技股份有限公司 一种与人gm-csf特异性结合的单克隆抗体及其检测试剂盒和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
AU3834589A (en) * 1988-05-31 1990-01-05 Schering Biotech Corporation Method of treating myeloid leukemias
IL95061A0 (en) 1989-07-14 1991-06-10 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1992008474A2 (fr) 1990-11-20 1992-05-29 The National Heart & Lung Institute Traitement des maladies pulmonaires
CA2060741A1 (fr) 1991-02-11 1992-08-12 Robert S. Greenfield Oligopeptides inhibant le gm-csf
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
EP0799244A1 (fr) * 1995-10-16 1997-10-08 Unilever N.V. Analogue de fragment d'anticorps bifonctionnel ou bivalent
US5662138A (en) * 1996-06-12 1997-09-02 Wang; Wen-Hsing Drop head structure
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
ES2609583T3 (es) * 2000-06-16 2017-04-21 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
WO2002024865A2 (fr) * 2000-09-19 2002-03-28 Microbia, Inc. Modulation de production de metabolites secondaires par des proteines en bouquet binucleaire a zinc
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7282205B2 (en) * 2001-11-07 2007-10-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis A virus antibodies
ATE444308T1 (de) * 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
UA89364C2 (en) 2003-12-03 2010-01-25 Биодженерикс Аг Granulocyte colony stimulating factor peptide conjugate (g-csf)
MXPA06006029A (es) 2003-12-03 2006-08-23 Neose Technologies Inc Factor de estimulacion de colonias de granulocitos modificado por glicopolietilenglicol.
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
WO2006011353A1 (fr) 2004-07-30 2006-02-02 Thk Co., Ltd. Procede de traitement de rainure filetee
ES2545769T3 (es) 2005-04-18 2015-09-15 Amgen Research (Munich) Gmbh Anticuerpos neutralizantes del factor estimulante de colonias de granulocitos y macrófagos humano
CA2608498C (fr) 2005-05-18 2017-04-04 Morphosys Ag Anticorps anti-gm-csf et leurs utilisations
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2007213716C1 (en) * 2006-02-08 2015-05-07 Eisai, Inc. Antigenic GM-CSF peptides and antibodies to GM-CSF
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2402013A1 (fr) 2006-11-21 2012-01-04 Kalobios Pharmaceuticals, Inc. Procédés pour le traitement de maladies inflammatoires chroniques au moyen d'un antagoniste GM-CSF
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PL2215119T3 (pl) 2007-11-13 2013-06-28 Evec Inc Przeciwciała monoklonalne, które wiążą się z hGM-CSF i kompozycje lecznicze je zawierające

Also Published As

Publication number Publication date
PL2215119T3 (pl) 2013-06-28
PE20091420A1 (es) 2009-10-17
EP2559706A1 (fr) 2013-02-20
US20140205611A1 (en) 2014-07-24
US20110182905A1 (en) 2011-07-28
SI2215119T1 (sl) 2013-04-30
CL2008003361A1 (es) 2010-02-05
NZ597023A (en) 2013-07-26
UY31466A1 (es) 2009-07-17
CO6382188A2 (es) 2012-02-15
ECSP10010251A (es) 2010-08-31
AR069290A1 (es) 2010-01-13
BRPI0820530A2 (pt) 2015-06-16
CN101970489A (zh) 2011-02-09
HRP20130204T1 (hr) 2013-04-30
IL205576A0 (en) 2010-11-30
KR20100102108A (ko) 2010-09-20
RU2013141223A (ru) 2015-03-20
TW200927760A (en) 2009-07-01
WO2009064399A1 (fr) 2009-05-22
CN104072613A (zh) 2014-10-01
TWI434854B (zh) 2014-04-21
ES2401536T3 (es) 2013-04-22
RU2517596C2 (ru) 2014-05-27
CN101970489B (zh) 2014-06-11
TW201206955A (en) 2012-02-16
RU2010123693A (ru) 2011-12-20
SG176499A1 (en) 2011-12-29
EP2215119B1 (fr) 2012-12-26
RS52713B (sr) 2013-08-30
MX2010005291A (es) 2010-11-12
MA31899B1 (fr) 2010-12-01
NZ586027A (en) 2012-01-12
EP2535353A8 (fr) 2013-04-03
HK1146729A1 (en) 2011-07-08
PT2215119E (pt) 2013-02-11
AU2008321429A1 (en) 2009-05-22
ZA201003467B (en) 2012-01-25
EP2535353A1 (fr) 2012-12-19
DK2215119T3 (da) 2013-02-04
EP2215119A1 (fr) 2010-08-11
CA2705539A1 (fr) 2009-05-22
ME01005B (fr) 2012-10-20
US8679502B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
CO6290643A2 (es) Derivados ciclopropilamina
PH12012501761A1 (en) Anti-nerve growth factor (ngf) antibody compositions
NZ590131A (en) Notch-binding agents and antagonists and methods of use thereof
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EP2582722A4 (fr) Anticorps contre gd2
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
WO2014012007A3 (fr) Agents de liaison des protéines rspo3 et leurs utilisations
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
CA2725873A1 (fr) Anticorps monoclonaux diriges contre un facteur de croissance fibroblastique basique
EA201100884A1 (ru) Моноклональные антитела анти-rhd
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
EA201390117A1 (ru) Композиция антител к vegfr-3
WO2008042941A3 (fr) Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse
UA102085C2 (ru) ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ
MX2025010390A (es) Anticuerpos muc1 y cd16a y metodos de uso
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
EA202092151A1 (ru) Антитела